The global biotechnology sector is experiencing a significant resurgence, marked by robust investment, strategic mergers and acquisitions, and groundbreaking scientific advancements, particularly within oncology. As the SPDR S&P Biotech ETF (XBI) soared by approximately 69% over the past year, and global life sciences M&A reached an astonishing $240 billion in 2025 – an 81% increase from the previous year, according to an EY report detailing a record $2.1 trillion in deal capacity – the industry is demonstrating renewed vitality. Goldman Sachs further projects a sharp rise in broader M&A volume throughout 2026, signaling a sustained period of transactional activity.
This optimistic outlook, however, belies a nuanced distribution of capital. "It really wasn’t until Q4 of last year that we started to see a rebound," observed Dr. Christiana Bardon, Managing Partner of MPM BioImpact, a Boston-based biotech investment firm overseeing roughly $3 billion, with a focus on fostering companies from their inception through public market entry. "I’m hoping we’re seeing the return of the generalist investor to the biotech sector." Evidence of this demand was palpable when Aktis Oncology, one of MPM BioImpact’s portfolio companies, completed its initial public offering in January, being 18 times oversubscribed. "That tells you how much demand there is for a high-quality, top-class asset priced appropriately," Dr. Bardon added, underscoring the market’s appetite for compelling, clinically validated innovations.
Despite this overall buoyancy, investment trends reveal a distinct preference for clinical-stage, de-risked assets. J.P. Morgan’s analysis for Q1 2026 recorded only 50 seed and Series A investments totaling $2.3 billion, a notable decline from 60 investments worth $3.7 billion during the same period a year prior. This trajectory positions first-time biotech financings for their lowest annual volume since before the pandemic, suggesting a more cautious early-stage investment climate. Concurrently, large pharmaceutical companies implemented substantial workforce reductions, cutting over 22,000 jobs in 2025, with these layoffs extending into the first half of 2026. This trend reflects a strategic recalibration, as larger players streamline operations and focus resources on late-stage pipeline assets and proven therapeutic areas.
Amidst these industry shifts, oncology continues to command a disproportionate share of investment, now representing over a quarter (approximately 32%) of biotech venture capital by deal value, up from 23% in 2020. This intense focus on cancer research and development was prominently showcased at the 2026 ASCO Annual Meeting in Chicago, the world’s largest oncology conference. This year’s meeting highlighted several pivotal advancements, including a revolutionary RAS inhibitor that significantly extended survival in metastatic pancreatic cancer, overall survival data for a Chinese-developed bispecific antibody poised to challenge the dominance of Merck’s Keytruda franchise, and a wave of strategic acquisitions signaling a major push to make cell therapy accessible beyond specialized academic centers.
The End of an Era for "Undruggable" Cancer: A Breakthrough in Pancreatic Cancer
For decades, the RAS family of oncogenes represented one of oncology’s most formidable challenges. Responsible for driving approximately 90% of pancreatic cancers, along with a significant proportion of lung and colorectal malignancies, RAS mutations remained stubbornly resistant to therapeutic intervention, earning the dreaded moniker "undruggable." The protein’s hydrophobic nature and lack of obvious binding pockets made it an elusive target for small molecule drugs, leading to countless research setbacks and limited progress for patients.
This long-standing paradigm shifted dramatically in April 2026, with Revolution Medicines announcing groundbreaking results for daraxonrasib, an oral RAS(ON) multi-selective inhibitor. In the Phase 3 RASolute 302 trial, daraxonrasib nearly doubled the median overall survival in patients with previously treated metastatic pancreatic cancer, reporting 13.2 months compared to 6.7 months for standard chemotherapy (Hazard Ratio [HR] 0.40, p < 0.0001). This unprecedented efficacy led to an FDA Breakthrough Therapy Designation for daraxonrasib, and the full results were presented in a highly anticipated ASCO plenary session on May 31.
The development of daraxonrasib represents the culmination of foundational research spanning over a decade. Key to this breakthrough was the work of UCSF’s Kevan Shokat, who, in 2013, first identified a druggable pocket on mutant KRAS, specifically the G12C variant. This initial discovery, while targeting a specific mutation, opened the door to a broader understanding of RAS biology. Subsequently, Frank McCormick, who led the NCI’s RAS Initiative, played a crucial role in coordinating efforts to tackle this complex target. Daraxonrasib, as a RAS(ON) multi-selective inhibitor, targets RAS in its active, signaling state, offering a broader approach than allele-specific inhibitors like sotorasib (AMG 510), which targets KRAS G12C. The image of AlphaFold 3 predicting the KRAS G12C mutant in complex with sotorasib highlights the sophisticated computational biology tools that have accelerated drug discovery in this challenging area, allowing researchers to visualize and design inhibitors with unprecedented precision.
Dr. Bardon emphasized the historical significance of this achievement. "Scientists have long called KRAS the ‘greasy ball,’ because the protein is hydrophobic with no obvious pockets for a drug to bind to," she explained. "We’ve never had a breakthrough before in pancreatic cancer; all we’ve had is mostly failure and very incremental contributions." She likened the impact of daraxonrasib to the transformative effect of EGFR therapies, such as Tagrisso, in lung cancer, which fundamentally altered treatment paradigms and dramatically improved patient outcomes. The success of daraxonrasib offers a beacon of hope for a patient population that has long faced a dismal prognosis, potentially ushering in a new era of targeted therapies for this aggressive disease and validating decades of persistent research against one of cancer’s most resilient adversaries.
A Chinese Innovation Reshapes Immunotherapy: The Rise of Ivonescimab
The past decade saw PD-1 inhibitors emerge as the cornerstone of cancer immunotherapy, revolutionizing treatment across numerous solid tumors and generating over $50 billion in combined annual revenue for pharmaceutical giants like Merck (Keytruda) and Bristol Myers Squibb (Opdivo). These checkpoint inhibitors work by blocking the PD-1 pathway, thereby unleashing the body’s immune system to attack cancer cells. However, a new challenger, ivonescimab, a bispecific antibody developed in China, is now poised to redefine the landscape of cancer immunotherapy.
Ivonescimab simultaneously blocks both PD-1 and Vascular Endothelial Growth Factor (VEGF), offering a dual mechanism of action. PD-1 blockade addresses immune evasion by cancer cells, while VEGF inhibition targets tumor angiogenesis (blood vessel formation) and also plays a role in suppressing the immune microenvironment. This combined approach is hypothesized to provide a more comprehensive anti-tumor effect than PD-1 monotherapy. Summit Therapeutics, which holds the rights to ivonescimab in certain territories, submitted a Biologics License Application (BLA) for the drug in EGFR-mutated non-small cell lung cancer (NSCLC) following TKI therapy, which the FDA accepted for filing in January 2026, setting a PDUFA date of November 14, 2026.
The ASCO 2026 meeting was a critical juncture for ivonescimab, with the presentation of overall survival (OS) data from the Phase 3 HARMONi-6 trial. This trial compared ivonescimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy in first-line squamous NSCLC, a highly challenging indication. The presentation of these OS data in a plenary session underscored the high expectations and potential impact of the drug.
Dr. Bardon highlighted the unexpected nature of ivonescimab’s success. "I don’t think I would have invested in a company starting this kind of molecule because we had no idea it would work," she admitted. "It was only because these drugs are generating clinical data very easily in China that we saw the data and were literally floored." This sentiment reflects a broader industry recognition that innovative approaches from emerging biotech hubs, particularly in China, are increasingly challenging established Western paradigms.
Should the HARMONi-6 overall survival data prove positive, the implications for the oncology market would be profound, extending far beyond lung cancer. Ivonescimab has already demonstrated strong progression-free survival (PFS) data against PD-1-based regimens in earlier studies, setting the stage for the crucial OS readout at ASCO. If superior OS is confirmed, ivonescimab could potentially establish itself as a new standard of care across a multitude of indications currently approved for PD-1 inhibitors. The industry’s rapid response is telling: "Last year, when the ivonescimab data first hit, nobody had a PD-1/VEGF in their pipeline. Surprise, surprise, this year they do," Dr. Bardon noted, pointing to the AACR pharma partnering event as evidence of this swift pipeline adaptation. "If this trial is positive, no pharma company, especially ones with PD-1s like Merck and BMS, can afford not to have a PD-1/VEGF." This suggests a seismic shift, compelling major players to either acquire or rapidly develop their own dual-targeting agents to remain competitive.
The Keytruda Conundrum: Patent Cliff, Biosimilars, and the Dual Threat
Merck & Co.’s Keytruda (pembrolizumab) has been an unprecedented success story, generating an astounding $31.7 billion in 2025 across its intravenous (IV) and recently approved subcutaneous (SC) formulations. The drug’s broad approval across 38 solid tumor indications solidified its position as the undisputed leader in cancer immunotherapy. However, the horizon for Keytruda is dominated by an looming patent cliff, with its core U.S. patent set to expire in 2028, marking the largest single patent cliff event in pharmaceutical history.
In anticipation of this challenge, Merck strategically launched Keytruda Qlex, a subcutaneous formulation of pembrolizumab, approved in September 2025. This "classic lifecycle management" strategy aims to migrate prescribers and patients to a new, patent-protected version before biosimilars can launch against the original IV formulation. Keytruda Qlex offers significant advantages, reducing administration time from a 30-minute IV infusion to as little as one minute for a subcutaneous injection, enhancing patient convenience and potentially easing the burden on healthcare infrastructure. This move is projected to capture a substantial portion of the existing Keytruda market, preserving revenue streams post-exclusivity.
The threat of biosimilars is very real. At least seven companies, including Samsung Bioepis, Sandoz, Celltrion, and Amgen, are actively developing pembrolizumab biosimilars, with FDA submissions expected as early as 2026. These biosimilars are designed to offer comparable efficacy and safety at a significantly lower cost, promising to increase patient access and reduce healthcare expenditures. Merck CEO Rob Davis has publicly expressed confidence in the company’s ability to navigate this transition, framing it as manageable. "I’m quite confident that we will be in a position at a minimum to go through a very shallow period post the LOE, returning in a few years to growth," he stated, hinting at Merck’s broader pipeline and strategic initiatives beyond Keytruda.
However, the competitive landscape for Keytruda extends beyond biosimilars. The potential success of ivonescimab introduces a formidable "next-generation" threat. Analysts at RBC Capital Markets noted in April that "market optimism is building" around ivonescimab’s results, suggesting they "could lead to accelerated FDA approval and begin to erode Merck’s dominance in first-line lung cancer." If ivonescimab demonstrates superior efficacy, it could not only capture new market share but also potentially shift treatment paradigms, diminishing the long-term market potential for both branded Keytruda and its biosimilar versions.
Dr. Bardon underscored the magnitude of this dual threat. "The LOE will dramatically affect Merck because of the huge revenue that drug generates," she said. "But the next chapter of that drug may be PD-1/VEGF. Imagine $60 billion of aggregate revenue across all PD-1s, and now imagine that all being replaced with a new drug targeting PD-1/VEGF. That’s why this is so huge." This scenario paints a picture where the "shallow period" Merck anticipates might be deeper and longer, challenged not just by cheaper copies, but by potentially more effective, innovative alternatives that could redefine the standard of care for a vast number of cancer patients.
Making Cell Therapy Ordinary: The Dawn of In Vivo CAR-T
While Keytruda Qlex simplified cancer treatment from a 30-minute infusion to a one-minute injection, the field’s most potent therapies for blood cancers – impacting nearly 200,000 Americans diagnosed annually with leukemias, lymphomas, and myelomas – remain far more challenging to deliver. Traditional CAR-T cell therapies, while capable of producing durable remissions in these hematological malignancies, are plagued by complexities: a slow and costly manufacturing process, reliance on highly specialized academic medical centers for administration, and a "vein-to-vein" time that can stretch for weeks, during which a patient’s disease can progress.
The limitations of traditional autologous CAR-T (using a patient’s own cells) spurred the development of allogeneic cell therapy (using donor cells), intended to create "off-the-shelf" treatments. However, as Dr. Bardon noted, this "turned out to be very difficult and not very effective," largely due to challenges like graft-versus-host disease and immune rejection, which limited their broad applicability and efficacy.
This has propelled the field into its third, transformative chapter: in vivo CAR-T, or programming cells inside the patient’s body. This innovative approach aims to circumvent the need for ex vivo (outside the body) cell extraction, genetic modification, and reinfusion. The promise is a dramatically simplified, potentially "off-the-shelf" therapy that could be administered in community clinics, much like a conventional drug.
Big pharmaceutical companies are making substantial bets on this paradigm shift. Eli Lilly’s acquisition of Orna Therapeutics for up to $2.4 billion in February 2026 exemplifies this trend. Orna’s pioneering technology utilizes engineered circular RNA delivered via lipid nanoparticles to reprogram a patient’s own cells into CAR-T cells directly within the body. Dr. Bardon, whose firm MPM BioImpact was an early investor in Orna, explained, "They use lipid nanoparticles to deliver circular RNA to a cell and make it a CAR-T inside the patient. This is utterly transformative because it would be off-the-shelf and could be used by community physicians."
This acquisition is part of a larger wave of strategic investments in in vivo cell therapy. Other notable deals include AbbVie’s $2.1 billion purchase of Capstan Therapeutics, Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, and AstraZeneca’s $1 billion deal for EsoBiotec. These significant investments underscore the industry’s conviction that in vivo cell therapy represents the future, addressing the critical issues of cost, accessibility, and manufacturing scalability that have limited the widespread adoption of current CAR-T treatments.
The implications of this shift are profound. By making cell therapy "ordinary," these advancements promise to democratize access to life-saving treatments for blood cancer patients. Reduced logistical hurdles, lower costs, and broader availability mean that more patients, including those in underserved areas or those too frail to undergo complex ex vivo procedures, could benefit. Furthermore, the simplicity of in vivo administration could pave the way for exploring CAR-T therapies in solid tumors, an area where ex vivo CAR-T has faced considerable challenges, potentially expanding the reach of this powerful modality far beyond its current scope.
A New Horizon in Oncology
The 2026 ASCO Annual Meeting has served as a powerful testament to the dynamic and rapidly evolving landscape of cancer treatment. From the long-awaited triumph over "undruggable" RAS mutations in pancreatic cancer to the emergence of next-generation immunotherapies challenging established blockbusters, and the transformative push towards making cell therapy universally accessible, the pace of innovation remains relentless. These advancements are not merely incremental improvements but represent fundamental shifts in how cancer is understood, diagnosed, and treated. As the biotech market continues its rebound, fueled by strategic investments and a fierce pursuit of unmet medical needs, the future of oncology promises more effective, more convenient, and more accessible therapies for patients worldwide. The developments highlighted at ASCO 2026 affirm that while challenges remain, the scientific community’s unwavering commitment to conquering cancer is yielding unprecedented progress.
